MacroGenics reports FY2025 net loss of $74.6M, cash $189.9M; pipeline data catalysts for 2026

MACROGENICS INC

Net loss $74.6M in 2025 vs $66.9M in 2024; revenue flat at $149.5M; cash $189.9M down from $201.7M.
Phase 1 data for MGC026 (B7-H3 ADC) expected mid-2026; MGC028 (ADAM9 ADC) data in H2 2026.
LINNET study of lorigerlimab under partial clinical hold; update expected mid-2026. IND for MGC030 on track for Q3 2026.
Cash runway guidance extended into late 2027 based on current cash and partner payments.
R&D expenses down 17% to $147.2M; SG&A down 45% to $39.2M due to cost reductions.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

MACROGENICS INC reported the year ended December 31, 2025 results: revenue $149.5 million.

Period: the year ended December 31, 2025
Revenue: $149.5 million
Result: reported results

Exact text from the filing

cash equivalents and marketable securities balance as of December 31, 2025, was $189.9 million, compared to $201.7 million as of December 31, 2024. • Revenue : Total revenue was $149.5 million for the year ended December 31, 2025, compared to $150.0 million for the year ended December 31, 2024. Total revenue included contract manufacturing revenue of $52.6 million for

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.